Form 4: Veracyte CEO Marc Stapley's RSU Tax Withholding

Veracyte CEO Marc Stapley reported a disposition of 7,914 shares of common stock to cover tax obligations related to RSU vesting, not a sale.

Summary

• Marc Stapley, Chief Executive Officer and Director of Veracyte, Inc. (VCYT), reported a transaction on September 2, 2025.
• 7,914 shares of common stock were disposed of at a price of $30.11 per share.
• This disposition was solely to satisfy tax withholding obligations in connection with the vesting of restricted stock units (RSUs) and does not represent a sale by Mr. Stapley.
• Following this transaction, Mr. Stapley beneficially owns 341,852 shares of common stock.
• The reported beneficial ownership also includes 529 shares purchased on July 31, 2025, through the Veracyte, Inc. Employee Stock Purchase Plan.

Sentiment

Score: 7

Explanation: The filing indicates a routine tax withholding transaction following RSU vesting, which is a positive sign of executive compensation. The additional purchase through an ESPP further reinforces management's commitment. No negative implications are present.

Positives

• The underlying event is the vesting of restricted stock units (RSUs), indicating compensation for the CEO.
• The CEO also purchased 529 shares through the Employee Stock Purchase Plan, demonstrating continued investment in the company.

Future Outlook

NA

Industry Context

This is a routine insider transaction filing that reflects standard executive compensation practices involving restricted stock units and employee stock purchase plans within the biotechnology or diagnostics industry. It does not provide broader industry trends.

Stakeholder Impact

• Shareholders: The vesting of RSUs and ESPP purchase by the CEO can be seen as a positive signal of management's alignment with shareholder interests. The tax withholding is a neutral event.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving tax withholding for RSU vesting and a small ESPP purchase. While the RSU vesting is a positive sign of executive compensation and the ESPP purchase shows continued insider investment, these events are not significant enough to warrant a change in investment recommendation based solely on this filing. It provides no new material information that would fundamentally alter the company's valuation or outlook.

Keywords

Veracyte, VCYT, Marc Stapley, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Tax Withholding, Employee Stock Purchase Plan, CEO, Director